Treatment of acute myeloid leukemia by directly targeting both leukemia stem cells and oncogenic molecule with specific scFv-immunolipoplexes as a deliverer

Medical Hypotheses

Volumn 70, Issue 1, 2008, Pages 122-127

  Wang, Guang Ping ^a   Qi, Zhen Hua ^a   Chen, Fang Ping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIBODY; CD135 ANTIGEN; FARNESYL TRANS TRANSFERASE; GLYCOPROTEIN P; HISTONE DEACETYLASE INHIBITOR; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOLIPOSOME; LIPOPLEX; LIPOSOME; PHOSPHATIDYLINOSITOL 3 KINASE; POLYPEPTIDE; PROTEIN BCL 2; PROTEIN BCL XL; RETINOIC ACID; SINGLE CHAIN ANTIBODY VARIABLE REGION FRAGMENT; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW; BONE MARROW CELL; CANCER THERAPY; CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; DRUG TARGETING; GENE DELIVERY SYSTEM; HEAVY CHAIN; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA CELL; LEUKEMIA REMISSION; LEUKEMIA STEM CELL; LEUKEMOGENESIS; LIGHT CHAIN; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; STEM CELL; TREATMENT PLANNING;

HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, MYELOID, ACUTE; NEOPLASM PROTEINS; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 36448995495     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.04.017     Document Type: Article

References (34)

1. Tallman M.S. Therapy of acute myeloid leukemia. Cancer Control 8 (2001) 62-78
2. Frelin C., Imbert V., Griessinger E., et al. Targeting NF-kappa B activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 105 (2005) 804-811
3. Tallman M.S., Gilliland D.G., and Rowe J.M. Drug therapy for acute myeloid leukemia. Blood 106 (2005) 1154-1163
4. Stone R.M., O'Donnell M.R., and Sekeres M.A. Acute myeloid leukemia. Hematol Am Soc Hematol Educ Program 98-117 (2004)
5. Guzman M.L., and Jordan C.T. Considerations for targeting malignant stem cells in leukemia. Cancer Control 11 (2004) 97-104
6. Guzman M.L., Neering S.J., Upchurch D., et al. Nuclear factor-kappa B is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98 (2001) 2301-2307
7. Wang G.P., Cao X.Y., Xin H.Y., Li Q., Qi Z.H., and Chen F.P. CD34(+)/CD123(+) cell sorting from the patients with leukemia by Midi MACS method(chinese). J Exp Hematol 14 (2006) 969-971
8. Levis M., Murphy K.M., Pham R., et al. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood 106 (2005) 673-680
9. Pollard J.A., Alonzo T.A., Gerbing R.B., et al. FLT3 internal tandem duplication in CD34+/CD33-precursors predicts poor outcome in acute myeloid leukemia. Blood 108 (2006) 2764-2769
10. Miyamoto T., Weissman I.L., and Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8; 21 chromosomal translocation. Proc Natl Acad Sci USA 97 (2000) 7521-7526
11. Laukkanen M.L., Teeri T.T., and Keinanen K. Lipid-tagged antibodies: bacterial expression and characterization of a lipoprotein - single-chain antibody fusion protein. Protein Eng 6 (1993) 449-454
12. Park J.W., Hong K., Carter P., et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA 92 (1995) 1327-1331
13. Park J.W., Kirpotin D.B., Hong K., et al. Tumor targeting using anti-Her2 immunoliposomes. J Control Release 74 (2001) 95-113
14. Pagnan G., Stuart D.D., Pastorino F., et al. Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects. J Natl Cancer Inst 92 (2000) 253-261
15. Xu L., Huang C.C., Huang W., et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther 1 (2002) 337-346
16. Bird R.E., Hardman K.D., Jacobson J.W., et al. Single-chain antigen-binding proteins. Science 242 (1988) 423-426
17. Worn A., and Pluckthun A. Stability engineering of antibody single-chain Fv fragments. J Mol Biol 305 (2001) 989-1010
18. Xu L., Tang W.H., Huang C.C., et al. Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol Med 7 (2001) 723-734
19. Xu L., Pirollo K.F., and Change E.H. Tumor-targeted p53 gene therapy enhances the efficacy of conventional chemo/radiotherapy. J Control Release 74 (2001) 115-128
20. Beg A., and Baltimore D. An essential role for NF-κB in preventing TNF-α induced cell death. Science 274 (1996) 782-784
21. Wang C.Y., Mayo M.W., Korneluk R.G., et al. NF-kappa B antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281 (1998) 1680-1683
22. Van Antwerp D.J., Martin S.J., Kafri T., et al. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274 (1996) 787-789
23. Guzman M.L., Swiderski C.F., Howard D.S., et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 99 (2002) 16220-16225
24. Gilliland D.G., Jordan C.T., and Felix C.A. The molecular basis of leukemia. Hematol Am Soc Hematol Educ Program 80-97 (2004)
25. Kiyoi H., and Naoe T. Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation. Int J Hematol 83 (2006) 301-308
26. Parcells B.W., Ikeda A.K., Simms-Waldrip T., Moore T.R., and Sakamoto K.M. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. Stem Cells 24 (2006) 1174-1184
27. Schessl C., Rawat V.P.S., Cusan M., et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest 115 (2005) 2159-2168
28. Peterson L.F., and Zhang D.E. The 8; 21 translocation in leukemogenesis. Oncogene 23 (2004) 4255-4262
29. Nimer S.D., and Moore M.A. Effects of the leukemia-associated AML1/ETO protein on hematopoietic stem and progenitor cells. Oncogene 23 (2004) 4249-4254
30. Heidenreich O., Krauter J., Riehle H., et al. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8; 21)-positive leukemic cells. Blood 101 (2003) 3157-3163
31. Dunne J., Cullmann C., Ritter M., et al. siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t (8; 21)-positive cell lines and primary AML blasts. Oncogene 25 (2006) 6067-6078
32. Jordan C.T., Guzman M.L., and Noble M. Cancer stem cells. New Engl J Med 355 (2006) 1253-1261
33. Schnittger S., Kohl T.M., Haferlach T., et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 107 (2006) 1791-1799
34. Wang Y.Y., Zhou G.B., Yin T., et al. AML1-ETO and C-KIT mutation/overexpression in t (8; 21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA 102 (2005) 1104-1109